Literature DB >> 24155091

Idiopathic portal hypertension: natural history and long-term outcome.

Sith Siramolpiwat1, Susana Seijo, Rosa Miquel, Annalisa Berzigotti, Angeles Garcia-Criado, Anna Darnell, Fanny Turon, Virginia Hernandez-Gea, Jaume Bosch, Juan Carlos Garcia-Pagán.   

Abstract

UNLABELLED: Idiopathic portal hypertension (IPH) is a rare cause of intrahepatic portal hypertension. Data on natural history and prognosis of IPH are limited. We sought to describe the complications and long-tem outcome of IPH by retrospectively studying 69 biopsy-proven cases of IPH. Mean duration of follow-up was 6.7 ± 4.6 years. All patients had evidence of portal hypertension (PH) at diagnosis, and 42% were symptomatic. Variceal bleeding (VB) was the most common manifestation. In those without bleeding at diagnosis, 74% had varices at first endoscopy. In those with large varices, the 1-year probability of first bleeding despite primary prophylaxis was 9%. The 1-year probability of rebleeding was 22%. Ascites and hepatic encephalopathy was documented in 26% and 7% of patients, respectively, at least once during the clinical course. The 1-year probability of developing portal vein thrombosis (PVT) was 9%, and 53% of patients receiving anticoagulation achieved recanalization. Human immunodeficiency virus (HIV) infection and VB at diagnosis were the independent predictors of PVT. Seven patients died (6 as a result of an IPH-related cause) and 2 were transplanted. Probability of liver transplantation-free survival was 82% at 10 years. Presence of a severe associated disorder and ascites as a presenting symptom were associated with poor survival.
CONCLUSION: Variceal bleeding is a major complication of IPH. Using, in IPH patients, the same management approach for PH as in cirrhosis is safe and maintains a low incidence of first bleeding and rebleeding in IPH patients. PVT is a frequent complication, particularly in those with HIV infection. Despite several complications, overall survival of patients with IPH is considerably good.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24155091     DOI: 10.1002/hep.26904

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

1.  Pediatric non-cirrhotic portal fibrosis: role of endoscopic management in determining long-term outcome.

Authors:  Durga Prasad; Moinak Sen Sarma; Surender Kumar Yachha; Anshu Srivastava; Ujjal Poddar
Journal:  Hepatol Int       Date:  2019-08-29       Impact factor: 6.047

2.  Long-term outcome of pediatric non-cirrhotic portal fibrosis from the viewpoint of endoscopic profile.

Authors:  Kohei Kotani; Norifumi Kawada
Journal:  Hepatol Int       Date:  2020-03-13       Impact factor: 6.047

3.  Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report.

Authors:  Alexandra Alexopoulou; Iliana Mani; Dina G Tiniakos; Flora Kontopidou; Ioanna Tsironi; Marina Noutsou; Helen Pantelidaki; Spyros P Dourakis
Journal:  World J Hepatol       Date:  2019-05-27

Review 4.  Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts.

Authors:  Dominique-Charles Valla; Dominique Cazals-Hatem
Journal:  Virchows Arch       Date:  2018-03-24       Impact factor: 4.064

Review 5.  Idiopathic portal hypertension and extrahepatic portal venous obstruction.

Authors:  Rajeev Khanna; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2018-02-20       Impact factor: 6.047

6.  Transient Elastography (Fibroscan) in Patients with Non-cirrhotic Portal Fibrosis.

Authors:  Praveen Sharma; Rachit Agarwal; Shashi Dhawan; Naresh Bansal; Vikas Singla; Ashish Kumar; Anil Arora
Journal:  J Clin Exp Hepatol       Date:  2017-03-14

7.  Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity.

Authors:  Ankur Varma; Susan C Abraham; Rohtesh S Mehta; Neeraj Y Saini; Medhavi Honhar; Munazza Rashid; Julianne Chen; Samer A Srour; Qaiser Bashir; Gabriela Rondon; Betul Oran; Chitra M Hosing; Yago Nieto; Partow Kebriaei; Amin M Alousi; Sairah Ahmed; David Marin; Issa F Khouri; Stefan O Ciurea; Muzaffar H Qazilbash; Katy Rezvani; Paolo Anderlini; Borje S Andersson; Elizabeth J Shpall; Richard E Champlin; Uday R Popat
Journal:  Blood Adv       Date:  2020-04-14

Review 8.  Morphometric changes and imaging findings of diffuse liver disease in relation to intrahepatic hemodynamics.

Authors:  Kumi Ozaki; Kazuto Kozaka; Yasuo Kosaka; Hirohiko Kimura; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2020-04-28       Impact factor: 2.374

Review 9.  Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.

Authors:  Michel Kmeid; Xiuli Liu; Samuel Ballentine; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2021-04-21

10.  Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension.

Authors:  Nikolaj Worm Ørntoft; Michel Blé; Anna Baiges; Jose Ferrusquia; Virginia Hernández-Gea; Fanny Turon; Marta Magaz; Søren Møller; Holger Jon Møller; Juan Carlos Garcia-Pagan; Henning Gronbaek
Journal:  Front Physiol       Date:  2021-06-11       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.